Ir a la página de inicio del Gobierno del Principado de Asturias

Datos del Documento

Utilice este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/13787


Título: Effects of calcitriol and paricalcitol on renal fibrosis in CKD
Autores: Martínez-Arias, Laura
Panizo, Sara
Alonso-Montes, Cristina
Martín-Vírgala, Julia
Martín-Carro, Beatriz
Fernández-Villabrille, Sara
Garcıa Gil-Albert, Carmen
Palomo-Antequera, Carmen
Fernndez-Martín, Jose Luis
Ruiz-Torres, María Piedad
Dusso, Adriana
Carrillo-López, Natalia
Cannata-Andía, Jorge B.
Naves-Díaz, Manuel
Palabras Claves: CKD
epithelial/mesenchymal-transition
inflammatory infiltration
renal fibrosis
VDRAs
Fecha Edición: Ene-2021
Editor: Nephrol Dial Transplant
Cita Bibliográfica: doi: 10.1093/ndt/gfaa373
Resumen: Background. In chronic kidney disease, the activation of the renin-angiotensin–aldosterone system (RAAS) and renal inflammation stimulates renal fibrosis and the progression to endstage renal disease. The low levels of vitamin D receptor (VDR) and its activators (VDRAs) contribute to worsen secondary hyperparathyroidismand renal fibrosis. Methods. The 7/8 nephrectomy model of experimental chronic renal failure (CRF) was used to examine the anti-fibrotic effects of treatment with two VDRAs, paricalcitol and calcitriol, at equivalent doses (3/1 dose ratio) during 4 weeks. Results. CRF increased the activation of the RAAS, renal inflammation and interstitial fibrosis. Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the RAAS through renal changes in renin, angiotensin receptor 1 (ATR1) and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leucocytes (CD45), a desintegrin and metalloproteinase mRNA, transforming growth factor beta mRNA and protein, and maintaining E-cadherin mRNA levels. Calcitriol showed similar trends without significant changes in most of these biomarkers. Conclusions. Paricalcitol effectively attenuated the renal interstitial fibrosis induced by CRF through a combination of inhibitory actions on the RAAS, inflammation and epithelial/mesenchymal transition.
URI: https://ria.asturias.es/RIA/handle/123456789/13787
Aparece en las Colecciones:Sanidad

Archivos en este documento:



Archivo TamañoFormato
Nephrol Dial Transplant 2021a.pdf268,73 kBAdobe PDFVer/Abrir



logo

Todos los documentos en RIA están protegidos por derechos de autor.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Contacto